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Genome-wide association analysis implicates
dysregulation of immunity genes in chronic
lymphocytic leukaemia
Phillip J. Law et al.#
Several chronic lymphocytic leukaemia (CLL) susceptibility loci have been reported; however,
much of the heritable risk remains unidentiﬁed. Here we perform a meta-analysis of six
genome-wide association studies, imputed using a merged reference panel of 1,000
Genomes and UK10K data, totalling 6,200 cases and 17,598 controls after replication. We
identify nine risk loci at 1p36.11 (rs34676223, P¼ 5.04 10 13), 1q42.13 (rs41271473,
P¼ 1.06 10 10), 4q24 (rs71597109, P¼ 1.37 10 10), 4q35.1 (rs57214277, P¼ 3.69
 108), 6p21.31 (rs3800461, P¼ 1.97 10 8), 11q23.2 (rs61904987, P¼ 2.64 10 11),
18q21.1 (rs1036935, P¼ 3.27 10 8), 19p13.3 (rs7254272, P¼4.67 10 8) and 22q13.33
(rs140522, P¼ 2.70 109). These new and established risk loci map to areas of active
chromatin and show an over-representation of transcription factor binding for the key
determinants of B-cell development and immune response.
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C
hronic lymphocytic leukaemia (CLL) is an indolent B-cell
malignancy that has a strong genetic component, as
evidenced by the eightfold increased risk seen in relatives
of CLL patients1. Our understanding of CLL genetics has been
transformed by genome-wide association studies (GWAS) that
have identiﬁed risk alleles for CLL2–9. So far, common genetic
variation at 33 loci has been shown to inﬂuence CLL risk.
Although projections indicate that additional risk variants for
CLL can be discovered by GWAS, the statistical power of the
individual existing studies is limited.
To gain a more comprehensive insight into CLL predisposition,
we analysed genome-wide association data from populations of
European ancestry from Europe, North America and Australia,
identifying nine new risk loci. Our ﬁndings provide additional
insights into the genetic and biological basis of CLL risk.
Results
Association analysis. After quality control, the six GWAS
provided single-nucleotide polymorphism (SNP) genotypes on
4,478 cases and 13,213 controls (Supplementary Tables 1 and 2).
To increase genomic resolution, we imputed 410 million SNPs
using the 1000 Genomes Project10 combined with UK10K11 as
reference. Quantile–Quantile (Q–Q) plots for SNPs with minor
allele frequency (MAF) 40.5% post imputation did not show
evidence of substantive overdispersion (l between 1.00 and 1.10
across the studies; Supplementary Fig. 1). Meta-analysing the
association test results from the six series, we derived joint odds
ratios per-allele and 95% conﬁdence intervals under a ﬁxed-
effects model for each SNP and associated P values. In this
analysis, associations for the established risk loci were consistent
in direction and magnitude of effect with previously reported
studies (Fig. 1 and Supplementary Table 3).
We identiﬁed 16 loci where at least one SNP showed evidence
of association with CLL (deﬁned as Po1.0 10 7 in ﬁxed-
effects meta-analysis of the six series) and which were not
previously implicated with CLL risk at genome-wide signiﬁcance
(that is, Po5.0 10 8; Table 1 and Supplementary Tables 4
and 5). Where the signal was provided by an imputed SNP, we
conﬁrmed the ﬁdelity of imputation by genotyping
(Supplementary Table 6). We substantiated the 16 SNPs using
de novo genotyping in two studies and in silico replication in two
additional studies, totalling 1,722 cases and 4,385 controls. Meta-
analysis of the discovery and replication studies revealed genome-
wide signiﬁcant associations for eight novel loci (Table 1) at
1p36.11 (rs34676223, P¼ 5.04 10 13), 1q42.13 (rs41271473,
P¼ 1.06 10 10), 4q35.1 (rs57214277, P¼ 3.69 10 8),
6p21.31 (rs3800461, P¼ 1.97 10 8), 11q23.2 (rs61904987,
P¼ 2.64 10 11), 18q21.1 (rs1036935, P¼ 3.27 10 8),
19p13.3 (rs7254272, P¼ 4.67 10 8) and 22q13.33 (rs140522,
P¼ 2.70 10 9). We also conﬁrmed 4q24 (rs71597109, P¼ 1.37
 10 10), which has previously been identiﬁed as a suggestive
risk locus9. Conditional analysis of GWAS data showed no
evidence for additional independent signals at these nine loci. In
the remaining seven loci that did not replicate with genome-wide
signiﬁcance, the 9q22.33 locus (rs7026022, P¼ 7.00 10 8)
remains suggestive (Supplementary Table 5). In analyses limited
to the exomes of 141 CLL cases from 66 families, we found no
evidence to suggest that any of the association signals might be a
consequence of linkage disequilibrium (LD) with a rare disruptive
coding variant.
Several of the newly identiﬁed risk SNPs map in or near to
genes with established roles in B-cell biology, hence representing
credible candidates for susceptibility to CLL. The 4q24 association
marked by rs71597109 (Fig. 2) maps to intron 1 of the gene
encoding BANK1 (B-cell scaffold protein with ankyrin repeats 1),
a B-cell-speciﬁc scaffold protein. SNPs at this locus have
been associated with systemic lupus erythematosus risk12.
BANK1 expression is only seen in functional B-cell antigen
receptor (BCR)-expressing B cells, mediating effects through
LYN-mediated tyrosine phosphorylation of inositol triphosphate
receptors. BANK1-deﬁcient mice display higher levels of mature B
cells and spontaneous germinal centre B cells13, while studies in
humans found lower BANK1 transcript levels in CLL versus
normal B cells14. The 19p13.3 association marked by rs7254272
(Fig. 2) maps 2.5 kb 50 to ZBTB7A (zinc ﬁnger and BTB domain-
containing protein 7a, alias LRF, leukaemia/lymphoma-related
factor, pokemon). ZBTB7A is a master regulator of B versus T
lymphoid fate. Loss of ZBTB7A results in aberrant activation of
the NOTCH pathway in lymphoid progenitors. NOTCH is
constitutively activated in CLL and is a determinant of resistance
to apoptosis in CLL cells. rs34676223 at 1p36.11 maps B10 kb
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Figure 1 | Manhattan plot of association P values. Shown are the genome-wide P values (two-sided) of410 million successfully imputed autosomal SNPs
in 4,478 cases and 13,213 controls from the discovery phase. Text labelled in red are previously identiﬁed risk loci, and text labelled in blue are newly
identiﬁed risk loci. The red horizontal line represents the genome-wide signiﬁcance threshold of P¼ 5.0 108.
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upstream of MDS2 (Fig. 2), which is the fusion partner of ETV6
in t(1;12)(p36;p13) myelodysplasia. Based on RNA sequencing
(RNA-seq) data from patients, MDS2 is overexpressed in CLL
versus normal cells and also differentially expressed between
two experimentally determined CLL subgroups14. The SNP
rs57214277 maps to 4q35.1 and resides B140 kb centromeric
to IRF2 (interferon regulatory factor 2, Fig. 2). Interferon (IFN)-
ab, a family of antiviral immune genes, induces IRF2 that inhibits
the reactivation of murine gamma herpesvirus15. Furthermore,
SNPs in strong LD with rs57214277 are associated with increased
expression of IRF2 as well as trans-regulation of a network of
genes in lipopolysaccharide and IFNg-treated monocytes16.
rs140522 maps to 22q13.33 (Fig. 2), which has previously
been associated with multiple sclerosis risk17. This region of LD
contains four genes, of which only NCAPH2 (non-SMC
condensin II complex subunit H2) shows differential expression
between CLL and normal B cells14 (B2.5-fold lower levels in
CLL), and plays an essential role in mitotic chromosome
assembly and segregation. rs41271473, rs3800461, rs61904987
and rs1036935 mark genes that have roles in WNT signalling
(RHOU), autophagy (C6orf106), transcriptional activation
(CXXC1), kinetochore association (SKA1, ZW10) and protein
degradation (USP28, TMPRSS5; Fig. 3).
New CLL risk SNPs and clinical phenotype. We tested for
differences in the associations by sex or age at diagnosis for
each of the nine risk SNPs using case-only analysis, and
observed no relationships (Supplementary Data 1). In addition,
case-only analysis in a subset of studies provided no evidence
for associations between risk SNP genotypes and IGVH
(immunoglobulin variable region heavy chain) mutation
subtype (Supplementary Data 1) or overall patient survival
(Supplementary Table 7). Collectively, these data suggest that
Table 1 | Summary results for SNPs associated with CLL risk.
SNP Locus Position (bp, hg19) Risk allele Data set RAF (case; control) OR 95% CI P value
rs34676223 1p36.11 23943735 C Discovery (0.74; 0.71) 1.16 (1.09; 1.22) 2.69 10 7
Replication (0.74; 0.69) 1.29 (1.18; 1.42) 4.69 10 8
Combined 1.19 (1.14; 1.25) 5.04 10 13
I2¼ 24% Phet¼0.23
rs41271473 1q42.13 228880296 G Discovery (0.81; 0.79) 1.19 (1.12; 1.26) 4.69 10 8
Replication (0.82; 0.79) 1.20 (1.08; 1.34) 5.59 104
Combined 1.19 (1.13; 1.26) 1.06 10 10
I2¼0% Phet¼0.95
rs71597109 4q24 102741002 C Discovery (0.72; 0.69) 1.17 (1.11; 1.24) 1.02 108
Replication (0.73; 0.71) 1.15 (1.05; 1.26) 3.46 10 3
Combined 1.17 (1.11; 1.22) 1.37 10 10
I2¼0% Phet¼0.78
rs57214277 4q35.1 185254772 T Discovery (0.44; 0.41) 1.14 (1.08; 1.19) 9.56 10 7
Replication (0.43; 0.39) 1.12 (1.03; 1.21) 0.011
Combined 1.13 (1.08; 1.18) 3.69 10 8
I2¼0% Phet¼0.53
rs3800461 6p21.31 34616322 C Discovery (0.13; 0.11) 1.21 (1.12; 1.31) 4.20 10 7
Replication (0.12; 0.11) 1.17 (1.03; 1.34) 0.014
Combined 1.20 (1.13; 1.28) 1.97 108
I2¼0% Phet¼0.69
rs61904987 11q23.2 113517203 T Discovery (0.14; 0.12) 1.23 (1.14; 1.32) 4.44 10 8
Replication (0.13; 0.12) 1.26 (1.12; 1.42) 1.20 104
Combined 1.24 (1.16; 1.32) 2.46 10 11
I2¼0% Phet¼0.83
rs1036935 18q21.1 47843534 A Discovery (0.25; 0.22) 1.17 (1.10; 1.24) 2.81 10 7
Replication (0.24; 0.22) 1.11 (1.01; 1.23) 0.028
Combined 1.15 (1.10; 1.21) 3.27 10 8
I2¼0% Phet¼0.65
rs7254272 19p13.3 4069119 A Discovery (0.20; 0.18) 1.18 (1.11; 1.26) 4.61 10 7
Replication (0.19; 0.18) 1.13 (1.01; 1.26) 0.026
Combined 1.17 (1.10; 1.23) 4.67 108
I2¼0% Phet¼0.55
rs140522 22q13.33 50971266 T Discovery (0.35; 0.32) 1.16 (1.10; 1.22) 2.20 10 8
Replication (0.35; 0.33) 1.10 (1.01; 1.2) 0.025
Combined 1.15 (1.10; 1.20) 2.70 10 9
I2¼0% Phet¼0.94
bp, base pair position; CLL, chronic lymphocytic leukaemia; I2, proportion of the total variation due to heterogeneity; OR, odds ratio; Phet, P-value for heterogeneity; RAF, risk allele frequency;
SNP, single-nucleotide polymorphism; 95% CI, 95% conﬁdence interval.
RAF is risk allele frequency across all of the discovery and replication data sets, respectively. ORs are derived with respect to the risk allele. Text in bold highlight the P-value in the combined data.
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these nine risk variants have generic effects on CLL develop-
ment rather than tumour progression per se.
Functional annotation of new risk loci. To gain insight into the
biological basis underlying the novel association signals, we ﬁrst
evaluated proﬁles for three histone marks (H3K4me1, H3K27ac
marking active chromatin and the repressive mark H3K27me3) at
each locus, in GM12878 lymphoblastoid cell line (LCL; ref. 18) as
well as primary CLL samples19 (Supplementary Fig. 2). We also
examined ATAC-seq proﬁles from CLL samples and primary B
cells as a marker of chromatin accessibility19,20. Since the
strongest associated GWAS SNP may not represent the causal
variant, we examined signals across an interval spanning all
variants in LD r240.2 with the sentinel SNP (based on the 1000
Genomes EUR reference panel). These data revealed regions of
active chromatin state at all nine risk loci, in at least one of the
cell types. Furthermore, based on the analyses of Hnisz et al.21,
ﬁve of the loci fall within regions designated as ‘super enhancers’
in either LCLs or CD19 B cells (Supplementary Fig. 2). Overall,
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Figure 2 | Regional plots of association results and recombination rates for new risk loci for chronic lymphocytic leukaemia. Results shown for 1p36.11,
4q24, 4q35.1, 19p13.3, 22q13.33 (a–e). Plots (drawn using visPig62) show association results of both genotyped (triangles) and imputed (circles) SNPs in
the GWAS samples and recombination rates.  log10 P values (y axes) of the SNPs are shown according to their chromosomal positions (x axes). The
sentinel SNP in each combined analysis is shown as a large circle or triangle and is labelled by its rsID. The colour intensity of each symbol reﬂects the
extent of LD with the top genotyped SNP, white (r2¼0) through to dark red (r2¼ 1.0). Genetic recombination rates, estimated using the 1000 Genomes
Project samples, are shown with a light blue line. Physical positions are based on NCBI build 37 of the human genome. Also shown are the chromatin-state
segmentation track (ChromHMM) for lymphoblastoid cells using data from the HapMap ENCODE Project, and the positions of genes and transcripts
mapping to the region of association.
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these ﬁndings suggest that the risk loci annotate regulatory
regions and may, therefore, have an impact on CLL risk through
modulation of enhancer or promoter activity.
Given the possibility that SNPs might inﬂuence enhancer or
promoter activity by causing changes in transcription factor (TF)
binding, we next evaluated the SNPs at each GWAS locus based
on their overlap with TF-binding sites. In the absence of
comprehensive TF chromatin immunoprecipitation sequencing
(ChIP-Seq) data from CLL samples, we used regions of chromatin
accessibility deﬁned by ATAC-seq data19 as a surrogate marker
for TF binding, identifying 47 SNPs in LD r240.2 with the
sentinel SNPs that also overlapped ATAC-seq peaks. Using
motifbreakR22 to predict whether these SNPs might disrupt TF-
binding motifs, we found 478 potentially disrupted motifs,
corresponding to 349 TF-binding sites (Supplementary
Table 7). Moreover, at 10 of the SNPs, the altered motif
matched the TFs bound in ChIP-seq data from the ENCODE
project (Supplementary Table 8 and Supplementary Fig. 3). In
particular, we noted that rs13149699 at 4q35 (r2¼ 0.83 with lead
SNP rs57214277) was predicted to disrupt SPI1 binding. In
addition, rs13149699 showed evidence of evolutionary constraint,
and in LCL ChIP-seq data, the SNP was bound by SPI1 as well as
other TFs with roles in B-cell function including IRF4, PAX5,
POU2F2 (alias OCT2) and RELA (Supplementary Table 8).
We explored whether there was any association between the
genotypes of the nine new risk SNPs and the transcript levels of
genes within 1Mb of each respective variant by performing
expression quantitative trait loci (eQTL) analysis using gene
expression proﬁles of 468 CLL cases. In addition, we inter-
rogated publicly accessible expression data on whole blood
and LCLs (Supplementary Data 2). There were signiﬁcant
(false discovery rate (FDR)o0.05) and consistent eQTLs between
rs3800461 and C6orf106, rs1036935 and SKA1, rs140522 and
ODF3B, and rs140522 and TYMP.
Biological inference of all CLL risk loci. Given our observation
that the nine novel risk loci annotate putative regulatory regions,
we sought to examine the epigenetic landscape of CLL risk loci on
a broader scale, evaluating the enrichment of both histone
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Figure 3 | Regional plots of association results and recombination rates for new risk loci for chronic lymphocytic leukaemia. Results shown for 1q42.13,
6p21.31, 11q23.2, 18q21.1 (a–d). Plots (drawn using visPig62) show association results of both genotyped (triangles) and imputed (circles) SNPs in the
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with the top genotyped SNP, white (r2¼0) through dark red (r2¼ 1.0). Genetic recombination rates, estimated using the 1000 Genomes Project samples,
are shown with a light blue line. Physical positions are based on NCBI build 37 of the human genome. Also shown are the chromatin-state segmentation
track (ChromHMM) for lymphoblastoid cells using data from the HapMap ENCODE Project, and the positions of genes and transcripts mapping to the
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modiﬁcations (N¼ 11) and TF binding (N¼ 82) in GM12878
LCLs, across the new and previously published CLL GWAS risk
SNPs. Using the variant set enrichment method of Cowper-Sal lari
et al.23, we identiﬁed regions of strong LD (deﬁned as r240.8
and D040.8) and determined the overlap between these variants
and ENCODE ChIP-seq data. Imposing a P value threshold of
5.37 10 4 (that is, 0.05/93, based on permutation), we identiﬁed
a signiﬁcant enrichment of histone marks associated with active
enhancer and promoter elements (HK4Me1, H3K27ac and
H3K9ac) as well as actively transcribed regions (H3K36me3). We
also identiﬁed an over-representation of TF binding for POLR2A,
IRF4, RUNX3, NFATC1, STAT5A, PML and WRNIP1 (Fig. 4). In
addition, although not statistically signiﬁcant, POU2F2 showed
evidence for enriched binding (P¼ 7.78 10 4). Several of these
TFs have established roles in B-cell function. OCT2, IRF4 and
RUNX3 have been shown to be targeted for hypomethylation in B
cells24. MYC is a direct target of IRF4 in activated B cells,
with IRF4 being itself a direct target of MYC transactivation.
It is noteworthy that variations at IRF4 and 8q24-MYC are
recognized risk factors for CLL2,3. Collectively, these ﬁndings
are consistent with CLL GWAS SNPs mapping within regions of
active chromatin state that exert effects on B-cell cis-regulatory
networks.
We investigated the genetic pathways between the gene
products in proximity to the GWAS SNPs using the LENS
pathway tool25. These gene products were primarily involved
in immune response, BCR-mediated signalling, apoptosis
and maintenance of chromosome integrity, as well as inter-
connectivity between the gene products (Fig. 5). Pathways that
were enriched included those related to interferon signalling and
apoptosis (Supplementary Data 3).
Impact of risk SNPs on heritability of CLL. By ﬁtting all SNPs
from GWAS simultaneously using Genome-wide Complex Trait
Analysis, the estimated heritability of CLL attributable to all
common variation is 34% (±5%), thus having potential to explain
57% of the overall familial risk. This estimate represents the
additive variance and, therefore, does not include the potential
impact of interactions or dominance effects or gene–environment
interactions, having an impact on CLL risk. The currently
identiﬁed risk SNPs (newly discovered and previously identiﬁed)
only account for 25% of the additive heritable risk.
Discussion
Besides providing additional evidence for genetic susceptibility to
CLL, the new and established risk loci identiﬁed further insights
into the biological basis of CLL development. These loci
annotate genes that participate in interconnecting cellular path-
ways, which are central to B-cell development. In particular, we
note the involvement of BCR-mediated signalling with immune
responses and apoptosis. Importantly, gene discovery initiatives
can have an impact on the successful development of new
therapeutic agents26. In this respect it is notable that Ibrutinib27
(a BTK inhibitor) and Idelalisib28 (a PI3KCD inhibitor) mediate
their effects through interference of BCR signalling, and Veneto-
clax29 targets the anti-apoptotic behaviour of BCL-2. The power
of our GWAS to identify common alleles conferring relative risks
of 1.2 or greater (such as the rs35923643 variant) is high (B80%).
Hence, there are unlikely to be many additional SNPs with similar
effects for alleles with frequencies greater than 0.2 in populations
of European ancestry. In contrast, our analysis had limited power
to detect alleles with smaller effects and/or MAFo0.1. Hence,
further GWAS studies in concert with functional analyses should
lead to additional insights into CLL biology and afford the
prospect of development of novel therapies.
Methods
Ethics. Collection of patient samples and associated clinicopathological informa-
tion was undertaken with written informed consent and relevant ethical review
board approval at respective study centres in accordance with the tenets of the
Declaration of Helsinki. Speciﬁcally, these centres are UK-CLL1 and UK-CLL2: UK
Multi-Research Ethics Committee (MREC 99/1/082); GEC: Mayo Clinic Institu-
tional Review Board, Duke University Institutional Review Board, University of
Utah, University of Texas MD Anderson Cancer Center Institutional Review
Board, National Cancer Institute, ATBC: NCI Special Studies Institutional Review
Board, BCCA: UBC BC Cancer Agency Research Ethics Board, CPS-II: American
Cancer Society, ENGELA: IRB00003888—Comite d’ Evaluation Ethique de
l’Inserm IRB #1, EPIC: Imperial College London, EpiLymph: International Agency
for Research on Cancer, HPFS: Harvard School of Public Health (HSPH) Insti-
tutional Review Board, Iowa-Mayo SPORE: University of Iowa Institutional Review
Board, Italian GxE: Comitato Etico Azienda Ospedaliero Universitaria di Cagliari,
Mayo Clinic Case–Control: Mayo Clinic Institutional Review Board, MCCS:
Cancer Council Victoria’s Human Research Ethics Committee, MSKCC:
Memorial Sloan-Kettering Cancer Center Institutional Review Board, NCI-SEER
(NCI Special Studies Institutional Review Board), NHS: Partners Human Research
Committee, Brigham and Women’s Hospital, NSW: NSW Cancer Council Ethics
Committee, NYU-WHS: New York University School of Medicine Institutional
Review Board, PLCO: (NCI Special Studies Institutional Review Board), SCALE:
Scientiﬁc Ethics Committee for the Capital Region of Denmark, SCALE: Regional
Ethical Review Board in Stockholm (Section 4) IRB#5, Utah: University of Utah
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Institutional Review Board, UCSF and UCSF2: University of California San
Francisco Committee on Human Research, Women’s Health Initiative (WHI):
Fred Hutchinson Cancer Research Center and Yale: Human Investigation
Committee, Yale University School of Medicine. Informed consent was obtained
from all participants. The diagnosis of CLL (ICD-10-CM C91.10, ICD-O M9823/3
and 9670/3) was established in accordance with the International Workshop on
Chronic Lymphocytic Leukemia guidelines30.
Genome-wide association studies. The meta-analysis was based on six
GWAS2,6,7,9 (Supplementary Tables 1 and 2). Brieﬂy, the six GWAS comprised—
UK-CLL1: 517 CLL cases and 2,698 controls; UK-CLL2: 1,403 CLL cases, 2,501
controls; Genetic Epidemiology of CLL (GEC) Consortium: 396 CLL cases and 296
controls; NHL GWAS Consortium: 1,851 CLL cases and 6,649 controls; UCSF: 214
CLL cases, 751 controls; Utah: 331 CLL cases, 420 controls.
Quality control of GWAS. Standard quality-control measures were applied to the
GWAS31. Speciﬁcally, individuals with low call rate (o95%) as well as all
individuals evaluated to be of non-European ancestry (using the HapMap version 2
CEU, JPT/CHB and YRI populations as a reference) were excluded. For apparent
ﬁrst-degree relative pairs, we removed the control from a case–control pair;
otherwise, we excluded the individual with the lower call rate. SNPs with a call rate
o95% were excluded as were those with a MAF o0.01 or displaying signiﬁcant
deviation from Hardy–Weinberg equilibrium (that is, Po10 6). GWAS data were
imputed to 410 million SNPs with the IMPUTE2 v2.3 software32 using a merged
reference panel consisting of data from 1000 Genomes Project (phase 1 integrated
release 3 March 2012)10 and UK10K (ref. 11). Genotypes were aligned to the
positive strand in both imputation and genotyping. Imputation was conducted
separately for each study, and in each the data were pruned to a common set of
SNPs between cases and controls before imputation. We set thresholds for
imputation quality to retain potential risk variants with MAF40.005 for
validation. Poorly imputed SNPs deﬁned by an information measure o0.80 were
excluded. Tests of association between imputed SNPs and CLL was performed
using logistic regression under an additive genetic model in SNPTESTv2.5 (ref. 33).
The adequacy of the case–control matching and possibility of differential
genotyping of cases and controls were formally evaluated using Q–Q plots of test
statistics (Supplementary Fig. 1). The inﬂation factor l was based on the 90% least-
signiﬁcant SNPs34. Where appropriate, principal components, generated using
common SNPs, were included in the analysis to limit the effects of cryptic
population stratiﬁcation that otherwise might cause inﬂation of test statistics.
Eigenvectors for the GWAS data sets were inferred using smartpca (part of
EIGENSOFT35) by merging cases and controls with Phase II HapMap samples.
Replication studies and technical validation. The 16 SNPs in the most pro-
mising loci were taken forward for de novo replication (Supplementary Table 2).
The UK replication series comprised 645 cases collected through the NCLLC
and Leicester Haematology Tissue Bank and 2,341 controls comprised 2,780
healthy individuals ascertained through the National Study of Colorectal Cancer
(1999–2006; ref. 36). These controls were the spouses or unrelated friends of
individuals with malignancies. None had a personal history of malignancy at the
time of ascertainment. Both cases and controls were British residents and had self-
reported European ancestry. The Mayo replication series comprised 407 newly
diagnosed cases and 1,207 clinic-based controls from the Mayo Clinic CLL
case–control study37. The eligibility criteria of the cases were age 20 years and
older, consented within 9 months of their initial diagnosis at presentation to Mayo
Clinic and no history of HIV. The eligibility criteria for the controls were age 20
years and older, a resident of Minnesota, Iowa or Wisconsin at the time of
appointment at Mayo Clinic, no history of lymphoma or leukaemia and no
history of HIV infection. Controls were frequency matched to the regional case
distribution on 5-year age group, sex and geographic area. In silico replication was
performed in 444 cases and 609 controls from International Cancer Genome
Consortium (ICGC), and 226 cases and 228 controls from the WHI study38,39.
The ﬁdelity of imputation as assessed by the concordance between imputed and
directly genotyped SNPs was examined in a subset of samples (Supplementary
Table 5). Replication genotyping of UK samples was performed using competitive
allele-speciﬁc PCR KASPar chemistry (LGC, Hertfordshire, UK); replication
genotyping of Mayo samples was performed using Sequenom MassARRAY
(Sequenom Inc., San Diego, CA, USA). Primers are listed in Supplementary
Table 9. Call rates for SNP genotypes were 495% in each of the replication series.
To ensure the quality of genotyping in all assays, at least two negative controls and
duplicate samples (showing a concordance of 499%) were genotyped at each
centre. To exclude technical artefacts in genotyping, we performed cross-platform
validation of 96 samples and sequenced a set of 96 randomly selected samples from
each case and control series to conﬁrm genotyping accuracy. Assays were found to
be performing robustly; concordance was 499%.
Meta-analysis. Meta-analyses were performed using the ﬁxed-effects inverse-
variance method based on the b estimates and s.e.’s from each study using META
v1.6 (ref. 40). Cochran’s Q-statistic to test for heterogeneity and the I2 statistic
to quantify the proportion of the total variation due to heterogeneity were
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calculated41. Using the meta-analysis summary statistics and LD correlations from
a reference panel of the 1000 Genomes Project combined with UK10K we used
Genome-wide Complex Trait Analysis to perform conditional association
analysis42. Association statistics were calculated for all SNPs conditioning on the
top SNP in each loci showing genome-wide signiﬁcance. This is carried out in a
step-wise manner.
Analysis of exome-sequencing data. Previously published exome-sequencing
data from 141 cases from 66 CLL families43 were interrogated to search for
deleterious (missense, nonsense, frameshift or splice site) variants within a genomic
interval spanning all SNPs with LD r240.2 with each index SNP. Positions
resulting in protein-altering changes were identiﬁed using the Ensembl Variant
Effect Predictor (version 78).
Mutational status. IGVH mutation status was determined according to the
BIOMED-2 protocols as described previously44. Sequence analysis was conducted
using the Chromas software version 2.23 (Applied Biosystems) and the
international immunogenetics information system database. In accordance with
published criteria, we classiﬁed sequences with a germline identity of Z98% as
unmutated and those with an identity of o98% as mutated.
Association between genotype and patient outcome. To examine the rela-
tionship between SNP genotype and patient outcome, we analysed two patient
series: (1) 356 patients from the UK Leukaemia Research Fund (LRF) CLL-4 trial45,
which compared the efﬁcacy of ﬂudarabine, chlorambucil and the combination of
ﬂudarabine plus cyclophosphamide; (2) 377 newly diagnosed patients from Mayo
Clinic who were prospectively followed. Cox-regression analysis was used to
estimate genotype-speciﬁc hazard ratios and 95% CIs with overall survival.
Statistical analyses were undertaken using R version 2.5.0.
eQTL analysis. eQTL analyses were performed by examining the gene expression
proﬁles of 452 CLL cases (Affymetrix Human Genome U219 Array)46. Additional
data were obtained by querying publicly available eQTL mRNA expression data
using MuTHER47, the Blood eQTL browser48 and data from the GTEx
consortium49. MuTHER contains expression data on LCLs, skin and adipose tissue
from 856 healthy twins. The Blood eQTL browser contains expression data
from 5,311 non-transformed peripheral blood samples. We used the whole-blood
RNA-seq data from GTEx, which consisted of data from 338 individuals.
Functional annotation. Novel risk SNPs and their proxies (that is, r240.2 in the
1000 Genomes EUR reference panel) were annotated for putative functional effect
based upon histone mark ChIP-seq/ChIPmentation data for H3K27ac, H3K4Me1
and H3K27Me3 from GM12878 (LCL)18 and primary CLL cells19. We searched
for overlap with ‘super-enhancer’ regions as deﬁned by Hnisz et al.21, restricting
the analysis to the GM12878 cell line and CD19þ B cells. We also interrogated
ATAC-seq data from CLL cells19 and primary B cells20. The novel risk SNPs
and their proxies (r240.2 as above) were intersected with regions of accessible
chromatin in CLL cells, as deﬁned by Rendeiro et al.19, which were used as a
surrogate for likely sites of TF binding. SNPs falling within accessible sites (n¼ 47)
were taken forward to TF-binding motif analysis and were also annotated for
genomic evolutionary rate proﬁling score50 as well as bound TFs based on
ENCODE project18 ChIP-seq data.
TF-binding disruption analysis. To determine whether the risk variants or
their proxies were disrupting motif-binding sites, we used the motifbreakR
package22. This tool predicts the effects of variants on TF-binding motifs, using
position probability matrices to determine the likelihood of observing a particular
nucleotide at a speciﬁc position within a TF-binding site. We tested the SNPs
by estimating their effects on over 2,800 binding motifs as characterized by
ENCODE51, FactorBook52, HOCOMOCO53 and HOMER54. Scores were
calculated using the relative entropy algorithm.
TF and histone mark enrichment analysis. To examine enrichment in speciﬁc TF
binding across risk loci, we adapted the variant set enrichment method of Cowper-
Sal lari et al.23. Brieﬂy, for each risk locus, a region of strong LD (deﬁned as r240.8
and D040.8) was determined, and these SNPs were termed the associated variant
set (AVS). TF ChIP-seq uniform peak data were obtained from ENCODE for the
GM12878 cell line, which included data for 82 TF and 11 histone marks. For each
of these marks, the overlap of the SNPs in the AVS and the binding sites was
determined to produce a mapping tally. A null distribution was produced by
randomly selecting SNPs with the same characteristics as the risk-associated SNPs,
and the null mapping tally calculated. This process was repeated 10,000 times, and
approximate P-values were calculated as the proportion of permutations where null
mapping tally was greater or equal to the AVS mapping tally. An enrichment score
was calculated by normalizing the tallies to the median of the null distribution.
Thus, the enrichment score is the number of s.d.’s of the AVS mapping tally from
the mean of the null distribution tallies.
Heritability analysis. We used genome-wide complex trait analysis42 to estimate
the polygenic variance (that is, heritability) ascribable to all genotyped and imputed
GWAS SNPs. SNPs were excluded based on low MAF (MAFo0.01), poor
imputation (info score o0.4) and evidence of departure from Hardy Weinberg
Equilibrium (HWE) (Po0.05). Individuals were excluded for poor imputation and
where two individuals were closely related. A genetic relationship matrix of pairs of
samples was used as input for the restricted maximum likelihood analysis to
estimate the heritability explained by the selected set of SNPs. To transform the
estimated heritability to the liability scale, we used the lifetime risk55,56 for CLL,
which is estimated to be 0.006 by SEER (http://seer.cancer.gov/statfacts/html/
clyl.html). The variance of the risk distribution due to the identiﬁed risk loci was
calculated as described by Pharoah et al.57, assuming that the relative risk when a
ﬁrst-degree relative has CLL is 8.5 (ref. 1).
Pathway analysis. To investigate the interaction between the gene products of the
GWAS hits, we performed a pathway analysis. We selected the closest coding genes
for the lead-associated SNPs and then performed pathway analysis using the LENS
tool25, which identiﬁes gene product and protein–protein interactions from
HPRD58 and BioGRID59. Enrichment of pathways was assessed using Fisher’s
exact test, comparing the overlap of the genes in the network with the genes in the
pathway. Pathway data were obtained from REACTOME60. Cytoscape was used to
perform network analyses61, and the Hive Plot was drawn using HiveR
(academic.depauw.edu/Bhanson/HiveR/HiveR.html).
Data availability. Genotype data that support the ﬁndings of this study have been
deposited in the database of Genotypes and Phenotypes (dbGAP) under accession
code phs000802.v2.p1 and in the European Genome-phenome Archive (EGA)
under accession codesEGAS00001000090, EGAD00001000195, EGAS00001000108,
EGAD00000000022 and EGAD00000000024.
Transcriptional proﬁling data from the MuTHER consortium that support the
ﬁndings of this work have been deposited in the European Bioinformatics Institute
(Part of the European Molecular Biology Laboratory, EMBL-EBI) under accession
code E-TABM-1140. Data from Blood eQTL have been deposited in the EBI-EMBL
under accession codes E-TABM-1036, E-MTAB-945 and E-MTAB-1708. GTEx
data are deposited in dbGaP under accession code phs000424.v6.p1. The remaining
data are contained within the paper and its Supplementary ﬁles or are available
from the authors upon reasonable request.
References
1. Goldin, L. R., Pfeiffer, R. M., Li, X. & Hemminki, K. Familial risk of
lymphoproliferative tumors in families of patients with chronic lymphocytic
leukemia: results from the Swedish Family-Cancer Database. Blood 104,
1850–1854 (2004).
2. Di Bernardo, M. C. et al. A genome-wide association study identiﬁes six
susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 40, 1204–1210
(2008).
3. Crowther-Swanepoel, D. et al. Common variants at 2q37.3, 8q24.21, 15q21.3
and 16q24.1 inﬂuence chronic lymphocytic leukemia risk. Nat. Genet. 42,
132–136 (2010).
4. Slager, S. L. et al. Genome-wide association study identiﬁes a novel
susceptibility locus at 6p21.3 among familial CLL. Blood 117, 1911–1916
(2011).
5. Slager, S. L. et al. Common variation at 6p21.31 (BAK1) inﬂuences the risk of
chronic lymphocytic leukemia. Blood 120, 843–846 (2012).
6. Berndt, S. I. et al. Genome-wide association study identiﬁes multiple risk loci
for chronic lymphocytic leukemia. Nat. Genet. 45, 868–876 (2013).
7. Speedy, H. E. et al. A genome-wide association study identiﬁes multiple
susceptibility loci for chronic lymphocytic leukemia. Nat. Genet. 46, 56–60
(2014).
8. Sava, G. P. et al. Common variation at 12q24.13 (OAS3) inﬂuences chronic
lymphocytic leukemia risk. Leukemia 29, 748–751 (2015).
9. Berndt, S. I. et al. Meta-analysis of genome-wide association studies discovers
multiple loci for chronic lymphocytic leukemia. Nat. Commun. 7, 10933 (2016).
10. The 1000 Genomes Project Consortium. A map of human genome variation
from population-scale sequencing. Nature 467, 1061–1073 (2010).
11. Huang, J. et al. Improved imputation of low-frequency and rare variants using
the UK10K haplotype reference panel. Nat. Commun. 6, 8111 (2015).
12. Kozyrev, S. V. et al. Functional variants in the B-cell gene BANK1 are
associated with systemic lupus erythematosus. Nat. Genet. 40, 211–216 (2008).
13. Aiba, Y. et al. BANK negatively regulates Akt activation and subsequent B cell
responses. Immunity 24, 259–268 (2006).
14. Ferreira, P. G. et al. Transcriptome characterization by RNA sequencing
identiﬁes a major molecular and clinical subdivision in chronic lymphocytic
leukemia. Genome Res. 24, 212–226 (2014).
15. Mandal, P. et al. A gammaherpesvirus cooperates with interferon-alpha/beta-
induced IRF2 to halt viral replication, control reactivation, and minimize host
lethality. PLoS Pathog. 7, e1002371 (2011).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14175
8 NATURE COMMUNICATIONS | 8:14175 |DOI: 10.1038/ncomms14175 | www.nature.com/naturecommunications
16. Fairfax, B. P. et al. Innate immune activity conditions the effect of regulatory
variants upon monocyte gene expression. Science 343, 1246949 (2014).
17. The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust
Case Control Consortium 2. Genetic risk and a primary role for cell-mediated
immune mechanisms in multiple sclerosis. Nature 476, 214–219 (2011).
18. de Souza, N. The ENCODE project. Nat. Methods 9, 1046 (2012).
19. Rendeiro, A. F. et al. Chromatin accessibility maps of chronic lymphocytic
leukaemia identify subtype-speciﬁc epigenome signatures and transcription
regulatory networks. Nat. Commun. 7, 11938 (2016).
20. Corces, M. R. et al. Lineage-speciﬁc and single-cell chromatin accessibility
charts human hematopoiesis and leukemia evolution. Nat. Genet. 10
1193–1203 (2016).
21. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell
155, 934–947 (2013).
22. Coetzee, S. G., Coetzee, G. A. & Hazelett, D. J. motifbreakR: an R/Bioconductor
package for predicting variant effects at transcription factor binding sites.
Bioinformatics 31, 3847–3849 (2015).
23. Cowper-Sal lari, R. et al. Breast cancer risk-associated SNPs modulate the
afﬁnity of chromatin for FOXA1 and alter gene expression. Nat. Genet. 44,
1191–1198 (2012).
24. Oakes, C. C. et al. DNA methylation dynamics during B cell maturation
underlie a continuum of disease phenotypes in chronic lymphocytic leukemia.
Nat. Genet. 48, 253–264 (2016).
25. Handen, A. & Ganapathiraju, M. K. LENS: web-based lens for enrichment and
network studies of human proteins. BMC Med. Genomics 8, S2 (2015).
26. Nelson, M. R. et al. The support of human genetic evidence for approved drug
indications. Nat. Genet. 47, 856–860 (2015).
27. Byrd, J. C. et al. Targeting BTK with Ibrutinib in relapsed chronic lymphocytic
leukemia. N. Engl. J. Med. 369, 32–42 (2013).
28. Furman, R. R. et al. Idelalisib and rituximab in relapsed chronic lymphocytic
leukemia. N. Engl. J. Med. 370, 997–1007 (2014).
29. Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic
lymphocytic leukemia. N. Engl. J. Med. 374, 311–322 (2016).
30. Hallek, M. et al. Guidelines for the diagnosis and treatment of chronic
lymphocytic leukemia: a report from the International Workshop on Chronic
Lymphocytic Leukemia updating the National Cancer Institute-Working
Group 1996 guidelines. Blood 111, 5446–5456 (2008).
31. Anderson, C. A. et al. Data quality control in genetic case-control association
studies. Nat. Protoc. 5, 1564–1573 (2010).
32. Howie, B. N., Donnelly, P. & Marchini, J. A ﬂexible and accurate genotype
imputation method for the next generation of genome-wide association studies.
PLoS Genet. 5, e1000529 (2009).
33. Marchini, J., Howie, B., Myers, S., McVean, G. & Donnelly, P. A new multipoint
method for genome-wide association studies by imputation of genotypes. Nat.
Genet. 39, 906–913 (2007).
34. Clayton, D. G. et al. Population structure, differential bias and genomic control in
a large-scale, case-control association study. Nat. Genet. 37, 1243–1246 (2005).
35. Price, A. L. et al. Principal components analysis corrects for stratiﬁcation in
genome-wide association studies. Nat. Genet. 38, 904–909 (2006).
36. Penegar, S. et al. National study of colorectal cancer genetics. Br. J. Cancer 97,
1305–1309 (2007).
37. Cerhan, J. R. et al. Design and validity of a clinic-based case-control study on
the molecular epidemiology of lymphoma. Int. J. Mol. Epidemiol. Genet. 2,
95–113 (2011).
38. Anderson, G. L. et al. Implementation of the Women’s Health Initiative study
design. Ann. Epidemiol. 13, S5–S17 (2003).
39. Berndt, S. I. et al. Meta-analysis of genome-wide association studies
discovers multiple loci for chronic lymphocytic leukemia. Nat. Commun. 7,
10933 (2016).
40. Liu, J. Z. et al. Meta-analysis and imputation reﬁnes the association of 15q25
with smoking quantity. Nat. Genet. 42, 436–440 (2010).
41. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis.
Stat. Med. 21, 1539–1558 (2002).
42. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for genome-
wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011).
43. Speedy, H. E. et al. Germline mutations in shelterin complex genes are
associated with familial chronic lymphocytic leukemia. Blood 128, 2319–2326
(2016).
44. van Krieken, J. H. et al. Improved reliability of lymphoma diagnostics via PCR-
based clonality testing: report of the BIOMED-2 concerted action BHM4-
CT98-3936. Leukemia 21, 201–206 (2007).
45. Catovsky, D. et al. Assessment of ﬂudarabine plus cyclophosphamide for
patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a
randomised controlled trial. Lancet 370, 230–239 (2007).
46. Puente, X. S. et al. Non-coding recurrent mutations in chronic lymphocytic
leukaemia. Nature 526, 519–524 (2015).
47. Grundberg, E. et al. Mapping cis- and trans-regulatory effects across multiple
tissues in twins. Nat. Genet. 44, 1084–1089 (2012).
48. Westra, H. J. et al. Systematic identiﬁcation of trans eQTLs as putative drivers
of known disease associations. Nat. Genet. 45, 1238–1243 (2013).
49. Ardlie, K. G. et al. The genotype-tissue expression (GTEx) pilot analysis:
multitissue gene regulation in humans. Science 348, 648–660 (2015).
50. Davydov, E. V. et al. Identifying a high fraction of the human genome to be under
selective constraint using GERPþ þ . PLoS Comput. Biol. 6, e1001025 (2010).
51. Kheradpour, P. & Kellis, M. Systematic discovery and characterization of
regulatory motifs in ENCODE TF binding experiments. Nucleic Acids Res. 42,
2976–2987 (2014).
52. Wang, J. et al. Sequence features and chromatin structure around the genomic
regions bound by 119 human transcription factors. Genome Res. 22, 1798–1812
(2012).
53. Kulakovskiy, I. V. et al. HOCOMOCO: a comprehensive collection of human
transcription factor binding sites models. Nucleic Acids Res. 41, D195–D202 (2013).
54. Heinz, S. et al. Simple combinations of lineage-determining transcription
factors prime cis-regulatory elements required for macrophage and B cell
identities. Mol. Cell 38, 576–589 (2010).
55. Lu, Y. et al. Most common ‘sporadic’ cancers have a signiﬁcant germline
genetic component. Hum. Mol. Genet. 23, 6112–6118 (2014).
56. Lee, S. H. et al. Estimation and partitioning of polygenic variation captured by
common SNPs for Alzheimer’s disease, multiple sclerosis and endometriosis.
Hum. Mol. Genet. 22, 832–841 (2013).
57. Pharoah, P. D., Antoniou, A. C., Easton, D. F. & Ponder, B. A. Polygenes, risk
prediction, and targeted prevention of breast cancer. N. Engl. J. Med. 358,
2796–2803 (2008).
58. Keshava Prasad, T. S. et al. Human Protein Reference Database--2009 update.
Nucleic Acids Res. 37, D767–D772 (2009).
59. Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2013 update.
Nucleic Acids Res. 41, D816–D823 (2013).
60. Croft, D. et al. The Reactome pathway knowledgebase. Nucleic Acids Res. 42,
D472–D477 (2014).
61. Smoot, M. E., Ono, K., Ruscheinski, J., Wang, P. L. & Ideker, T. Cytoscape 2.8:
new features for data integration and network visualization. Bioinformatics 27,
431–432 (2011).
62. Scales, M., Jager, R., Migliorini, G., Houlston, R. S. & Henrion, M. Y. visPIG--a
web tool for producing multi-region, multi-track, multi-scale plots of genetic
data. PLoS ONE 9, e107497 (2014).
Acknowledgements
In the United Kingdom, Bloodwise provided funding for the study (LRF05001, LRF06002
and LRF13044) with additional support from Cancer Research UK (C1298/A8362 sup-
ported by the Bobby Moore Fund) and the Arbib Fund. G.P.S. is in receipt of a PhD
studentship from The Institute of Cancer Research. The NCI/InterLymph NHL GWAS
initiative was supported by the intramural programme of the Division of Cancer
Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health.
ATBC—This research was supported in part by the Intramural Research Program of the
NIH and the National Cancer Institute. In addition, this research was supported by U.S.
Public Health Service contracts N01-CN-45165, N01-RC-45035, N01-RC-37004 and
HHSN261201000006C from the National Cancer Institute, Department of Health and
Human Services. BC—Canadian Institutes for Health Research (CIHR); Canadian
Cancer Society; Michael Smith Foundation for Health Research. CPS-II—The Cancer
Prevention Study-II (CPS-II) Nutrition Cohort is supported by the American Cancer
Society. Genotyping for all CPS-II samples was supported by the Intramural Research
Program of the National Institutes of Health, NCI, Division of Cancer Epidemiology and
Genetics. We also acknowledge the contribution to this study from central cancer
registries supported through the Centers for Disease Control and Prevention National
Program of Cancer Registries, and cancer registries supported by the National Cancer
Institute Surveillance Epidemiology and End Results program. ELCCS—Leukemia and
Lymphoma Research. ENGELA—Association pour la Recherche contre le Cancer (ARC),
Institut National du Cancer (INCa), Fondation de France, Fondation contre la Leuce´mie,
Agence nationale de se´curite´ sanitaire de l’alimentation, de l’environnement et du travail
(ANSES). EPIC—Coordinated Action (Contract #006438, SP23-CT-2005-006438);
HuGeF (Human Genetics Foundation), Torino, Italy; Cancer Research UK. EpiLymph—
European Commission (grant references QLK4-CT-2000-00422 and FOOD-CT-2006-
023103); the Spanish Ministry of Health (grant references CIBERESP, PI11/01810,
PI14/01219, RCESP C03/09, RTICESP C03/10 and RTIC RD06/0020/0095), the Marato´
de TV3 Foundation (grant reference 051210), the Age`ncia de Gestio´d’AjutsUniversitarisi
de Recerca—Generalitat de Catalunya (grant reference 2014SRG756), who had no role in
the data collection, analysis or interpretation of the results; the NIH (contract NO1-
CO-12400); the Compagnia di San Paolo—Programma Oncologia; the Federal Ofﬁce for
Radiation Protection grants StSch4261 and StSch4420, the Jose´ Carreras Leukemia
Foundation grant DJCLS-R12/23, the German Federal Ministry for Education and
Research (BMBF-01-EO-1303); the Health Research Board, Ireland, and Cancer Research
Ireland; Czech Republic supported by MH CZ—DRO (MMCI, 00209805) and
RECAMO, CZ.1.05/2.1.00/03.0101; Fondation de France and Association de Recherche
Contre le Cancer. GEC/Mayo GWAS—National Institutes of Health (CA118444,
CA148690, CA92153). Intramural Research Program of the NIH, National Cancer
Institute. Veterans Affairs Research Service. Data collection for Duke University was
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14175 ARTICLE
NATURE COMMUNICATIONS | 8:14175 |DOI: 10.1038/ncomms14175 | www.nature.com/naturecommunications 9
supported by a Leukemia and Lymphoma Society Career Development Award, the
Bernstein Family Fund for Leukemia and Lymphoma Research and the National
Institutes of Health (K08CA134919), National Center for Advancing Translational
Science (UL1 TR000135). HPFS—The HPFS was supported in part by National Institutes
of Health grants CA167552, CA149445 and CA098122. We would like to thank the
participants and staff of the Health Professionals Follow-up Study for their valuable
contributions as well as the following state cancer registries for their help: AL, AZ, AR,
CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY,
NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, WY. We assume full responsibility
for analyses and interpretation of these data. Iowa-Mayo SPORE—NCI Specialized
Programs of Research Excellence (SPORE) in Human Cancer (P50 CA97274); National
Cancer Institute (P30 CA086862, P30 CA15083); Henry J. Predolin Foundation. Italian
GxE—Italian Association for Cancer Research (AIRC, Investigator Grant 11855; PC);
Fondazione Banco di Sardegna 2010–2012 and Regione Autonoma della Sardegna
(LR7 CRP-59812/2012; MGE). Mayo Clinic Case–Control—National Institutes of Health
(R01 CA92153); National Cancer Institute (P30 CA015083). MCCS—The Melbourne
Collaborative Cohort Study recruitment was funded by VicHealth and Cancer Council
Victoria. The MCCS was further supported by Australian NHMRC grants 209057,
251553 and 504711 and by infrastructure provided by Cancer Council Victoria. Cases
and their vital status were ascertained through the Victorian Cancer Registry (VCR). MD
Anderson—Institutional support to the Center for Translational and Public Health
Genomics. MSKCC—Geoffrey Beene Cancer Research Grant, Lymphoma Foundation
(LF5541); Barbara K. Lipman Lymphoma Research Fund (74419); Robert and Kate
Niehaus Clinical Cancer Genetics Research Initiative (57470); U01 HG007033;
ENCODE; U01 HG007033. R21 CA178800. NCI-SEER—Intramural Research Program
of the National Cancer Institute, National Institutes of Health and Public Health Service
(N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, N02-PC-71105).
NHS—The NHS was supported in part by National Institutes of Health grants
CA186107, CA87969, CA49449, CA149445 and CA098122. We would like to thank the
participants and staff of the Nurses’ Health Study for their valuable contributions as well
as the following state cancer registries for their help: A.L., A.Z., A.R., C.A., C.O., C.T.,
D.E., F.L., G.A., I.D., I.L., I.N., I.A., K.Y., L.A., M.E., M.D., M.A., M.I., N.E., N.H., N.J.,
N.Y., N.C., N.D., O.H., O.K., O.R., P.A., R.I., S.C., T.N., T.X., V.A., W.A. and W.Y.
The authors assume full responsibility for analyses and interpretation of these data.
NSW—NSW was supported by grants from the Australian National Health and Medical
Research Council (ID990920), the Cancer Council NSW and the University of
Sydney Faculty of Medicine. NYU-WHS—National Cancer Institute (R01 CA098661,
P30 CA016087); National Institute of Environmental Health Sciences (ES000260).
PLCO—This research was supported by the Intramural Research Program of the
National Cancer Institute and by contracts from the Division of Cancer Prevention,
National Cancer Institute, NIH, DHHS. SCALE—Swedish Cancer Society (2009/659).
Stockholm County Council (20110209) and the Strategic Research Program in
Epidemiology at Karolinska Institute. Swedish Cancer Society grant (02 6661). National
Institutes of Health (5R01 CA69669-02); Plan Denmark. UCSF2—The UCSF studies
were supported by the NCI, National Institutes of Health, CA1046282, CA154643,
CA45614, CA89745, CA87014. The collection of cancer incidence data used in this study
was supported by the California Department of Health Services as part of the statewide
cancer reporting programme mandated by California Health and Safety Code Section
103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results
Program under contract HHSN261201000140C awarded to the Cancer Prevention
Institute of California, contract HHSN261201000035C awarded to the University of
Southern California, and contract HHSN261201000034C awarded to the Public Health
Institute; and the Centers for Disease Control and Prevention’s National Program of
Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public Health
Institute. The ideas and opinions expressed herein are those of the authors, and
endorsement by the State of California, the California Department of Health Services, the
National Cancer Institute or the Centers for Disease Control and Prevention or their
contractors and subcontractors is not intended nor should be inferred. UTAH—National
Institutes of Health CA134674. Partial support for data collection at the Utah site was
made possible by the Utah Population Database (UPDB) and the Utah Cancer Registry
(UCR). Partial support for all data sets within the UPDB is provided by the Huntsman
Cancer Institute (HCI) and the HCI Comprehensive Cancer Center Support grant, P30
CA42014. The UCR is supported in part by NIH contract HHSN261201000026C from
the National Cancer Institute SEER Program with additional support from the Utah State
Department of Health and the University of Utah. WHI—WHI investigators are:
Program Ofﬁce (National Heart, Lung, and Blood Institute, Bethesda, Maryland)—
Jacques Rossouw, Shari Ludlam, Dale Burwen, Joan McGowan, Leslie Ford and Nancy
Geller; Clinical Coordinating Center (Fred Hutchinson Cancer Research Center, Seattle,
WA)—Garnet Anderson, Ross Prentice, Andrea LaCroix and Charles Kooperberg;
Investigators and Academic Centers (Brigham and Women’s Hospital, Harvard Medical
School, Boston, MA, USA)—JoAnn E. Manson; (MedStar Health Research Institute/
Howard University, Washington, DC, USA) Barbara V. Howard; (Stanford Prevention
Research Center, Stanford, CA, USA) Marcia L. Stefanick (The Ohio State University,
Columbus, OH, USA); Rebecca Jackson (University of Arizona, Tucson/Phoenix, AZ,
USA); Cynthia A. Thomson; (University at Buffalo, Buffalo, NY, USA); Jean Wactawski-
Wende (University of Florida, Gainesville/Jacksonville, FL, USA); Marian Limacher
(University of Iowa, Iowa City/Davenport, IA, USA); Robert Wallace (University of
Pittsburgh, Pittsburgh, PA, USA); Lewis Kuller (Wake Forest University School of
Medicine, Winston-Salem, NC, USA); Sally Shumaker WHI Memory Study (Wake
Forest University School of Medicine, Winston-Salem, NC, USA) Sally Shumaker.
The WHI programme is funded by the National Heart, Lung, and Blood Institute,
National Institutes of Health, U.S. Department of Health and Human Services through
contracts HHSN268201100046C, HHSN268201100001C, HHSN268201100002C,
HHSN268201100003C, HHSN268201100004C and HHSN271201100004C. YALE—
National Cancer Institute (CA62006); National Cancer Institute (CA165923). The
Spanish replication study was supported by the Spanish Ministry of Economy and
Competitiveness through the Instituto de Salud Carlos III (FIS PI13/01136; International
Cancer Genome Consortium-Chronic Lymphocytic Leukemia Genome Project). We
thank L. Padyukov (Karolinska Institutet) and the Epidemiological Investigation of
Rheumatoid Arthritis (EIRA) group for providing control samples from the Swedish
population for the Swedish replication study. MCCS cohort recruitment was funded by
VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian
NHMRC grants 209057, 251553 and 504711, and by infrastructure provided by Cancer
Council Victoria. Cases and their vital status were ascertained through the Victorian
Cancer Registry (VCR) and the Australian Institute of Health and Welfare (AIHW),
including the National Death Index and the Australian Cancer Database. This study
makes use of data generated by the Wellcome Trust Case Control Consortium. A full list
of the investigators who contributed to the generation of the data is available in
www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under
award 076113. We are grateful to all investigators and all the patients and individuals for
their participation. We also thank the clinicians, other hospital staff and study staff that
contributed to the blood sample and data collection for this study.
Author contributions
R.H. and S.L.S. developed the project and provided overall project management; R.H.,
S.L.S., P.J.L., H.E.S. and G.P.S. drafted the manuscript. At the ICR: P.J.L., G.P.S.
and H.E.S. performed bioinformatic and statistical analyses; H.E.S. performed project
management and supervised genotyping; G.P.S. and A.H. performed sequencing and
genotyping. In Newcastle, J.M.A. and D.J.A. conceived of the NCLLC; J.M.A. obtained
ﬁnancial support, supervised laboratory management and oversaw genotyping of cases
with NCLLC; N.J.S. and H.M. performed sample management of cases; A.G.H. developed
the Newcastle Haematology Biobank, incorporating NCLLC; and T.M.-F., G.H.J., G.S.,
R.J.H., A.R.P., D.J.A., J.R.B., G.P., C.P. and C.F. developed protocols for recruitment of
individuals with CLL and sample acquisition and performed sample collection of cases.
In Leicester, M.J.S.D. performed overall management, collection and processing of
samples; S.J. and A.M. performed DNA extractions and IGVH mutation assays. In Spain,
S.B., G.C., D.M.-G., I.Q., A.C. and E.C. performed sample collection, genotyping and
expression analysis in CLL cells. In Sweden, L.M. and R.R. performed collection of cases,
and H.H. and K.E.S. performed sample collection in the Scandinavian Lymphoma
Etiology (SCALE) study. At NCI GWAS/GEC GWAS, S.S., S.I.B., N.R. and S.J.C.
conducted and supervised the genotyping of samples. S.I.B., N.J.C., C.F.S., J.V., A.N.,
A.M., L.R.G., L.R.T., B.M.B., S.J., W.C., K.E.S., Q.L., A.R.B.-W., M.P.P., C.M.V., P.C.,
Y.Z., T.Z., G.G.G., C.L., T.G.C., M.L., M. Melbye, B.G., M.G., K.C., W.R.D., B.K.L., L.C.,
P.M.B., E.A.H., R.D.J., L.F.T., Y.B., P. Boffetta, P. Brennan, M. Maynadie, J.M., D.A.,
S.W., Z.W., N.E.C., L.M.M., R.K.S., E.R., P.V., R.C.H.V., M.C.S., R.L.M., J.C., S.T., J.J.S.,
P.K., M.G.E., G.S., G.F., R.J.H., L.M., A.R.P., K.E.N., J.F.F., K.O., H.H., S.J.C., R.R., S.d.S.,
J.R.C., N.R. and S.L.S. conducted the epidemiological studies and contributed samples to
the GWAS. Utah GWAS: N.J.C. designed and directed all aspects of the study; M.G.
provided clinical oversight; K.C. provided statistical expertise. UCSF GWAS: C.S.
supervised all aspects of the overall study; P.M.B. provided project management; L.C.
performed bioinformatic and statistical analyses.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing ﬁnancial interests: The authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Law, P. J. et al. Genome-wide association analysis implicates
dysregulation of immunity genes in chronic lymphocytic leukaemia. Nat. Commun. 8,
14175 doi: 10.1038/ncomms14175 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
r The Author(s) 2017
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14175
10 NATURE COMMUNICATIONS | 8:14175 |DOI: 10.1038/ncomms14175 | www.nature.com/naturecommunications
Philip J. Law1,*, Sonja I. Berndt2,*, Helen E. Speedy1,*, Nicola J. Camp3,*, Georgina P. Sava1,*, Christine F. Skibola4,*,
Amy Holroyd1, Vijai Joseph5, Nicola J. Sunter6, Alexandra Nieters7, Silvia Bea8, Alain Monnereau9,10,11, David
Martin-Garcia8, Lynn R. Goldin2, Guillem Clot8, Lauren R. Teras12, Ine´s Quintela13, Brenda M. Birmann14, Sandrine
Jayne15, Wendy Cozen16,17, Aneela Majid15, Karin E. Smedby18, Qing Lan2, Claire Dearden19, Angela R. Brooks-
Wilson20,21, Andrew G. Hall6, Mark P. Purdue2, Tryfonia Mainou-Fowler22, Claire M. Vajdic23, Graham H.
Jackson24, Pierluigi Cocco25, Helen Marr6, Yawei Zhang26, Tongzhang Zheng26, Graham G. Giles27,28, Charles
Lawrence29, Timothy G. Call30, Mark Liebow31, Mads Melbye32,33, Bengt Glimelius34, Larry Mansouri34, Martha
Glenn3, Karen Curtin3, W Ryan Diver35, Brian K. Link36, Lucia Conde4, Paige M. Bracci37, Elizabeth A. Holly37,
Rebecca D. Jackson38, Lesley F. Tinker39, Yolanda Benavente40,41, Paolo Boffetta42, Paul Brennan43, Marc
Maynadie44, James McKay43, Demetrius Albanes2, Stephanie Weinstein2, Zhaoming Wang45, Neil E.
Caporaso2, Lindsay M. Morton2, Richard K. Severson46, Elio Riboli47, Paolo Vineis48,49, Roel C.H. Vermeulen50,51,
Melissa C. Southey52, Roger L. Milne27,28, Jacqueline Clavel53,54, Sabine Topka5, John J. Spinelli55,56, Peter
Kraft57,58, Maria Grazia Ennas59, Geoffrey Summerﬁeld60, Giovanni M. Ferri61, Robert J. Harris62, Lucia Miligi63,
Andrew R. Pettitt62, Kari E. North64,65, David J. Allsup66, Joseph F. Fraumeni Jr2, James R. Bailey66, Kenneth Ofﬁt5,
Guy Pratt67, Henrik Hjalgrim32, Chris Pepper68, Stephen J. Chanock2, Chris Fegan69, Richard Rosenquist34, Silvia de
Sanjose42,43, Angel Carracedo13,70, Martin J.S. Dyer15, Daniel Catovsky71, Elias Campo8,72, James R. Cerhan73,
James M. Allan6, Nathanial Rothman2, Richard Houlston1,** & Susan L. Slager73,**
1 Division of Genetics and Epidemiology, The Institute of Cancer Research, London SW7 3RP, UK. 2 Division of Cancer Epidemiology and Genetics, National
Cancer Institute, Bethesda, Maryland 20892, USA. 3 Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine,
Salt Lake City, Utah 84112, USA. 4Department of Epidemiology, School of Public Health and Comprehensive Cancer Center, University of Alabama at
Birmingham, Birmingham, Alabama 35233, USA. 5Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
6Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. 7 Center for Chronic Immunodeﬁciency, University
Medical Center Freiburg, Freiburg, Baden-Wu¨rttemberg 79108, Germany. 8 Institut d’Investigacions Biome`diques August Pi iSunyer (IDIBAPS), Hospital
Clı´nic, Barcelona 08036, Spain. 9Registre des he´mopathies malignes de la Gironde, Institut Bergonie´, Inserm U1219 EPICENE, 33076 Bordeaux, France.
10 Epidemiology of Childhood and Adolescent Cancers Group, Inserm, Center of Research in Epidemiology and Statistics Sorbonne Paris Cite´ (CRESS), Paris
F-94807, France. 11 Universite´ Paris Descartes, Paris 75270, France. 12 Epidemiology Research Program, American Cancer Society, Atlanta, Georgia 30303,
USA. 13 Grupo de Medicina Xenomica, Universidade de Santiago de Compostela, Centro Nacional de Genotipado (CeGen-PRB2-ISCIII), CIBERER, 15782
Santiago de Compostela, Spain. 14 Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical
School, Boston, Massachusetts 02115, USA. 15 Ernest and Helen Scott Haematological Research Institute, University of Leicester, Leicester LE2 7LX, UK.
16 Department of Preventive Medicine, USC Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA. 17 Norris
Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA. 18 Unit of Clinical
Epidemiology, Department of Medicine Solna, Karolinska Institutet, Hematology Center, Karolinsak University Hospital, Stockholm 17176, Sweden. 19 The
Royal Marsden NHS Foundation Trust, London SM2 5PT, UK. 20Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada V5Z1L3.
21 Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, British Columbia, Canada V5A1S6. 22Haematological Sciences,
Medical School, Newcastle University, Newcastle-upon-Tyne NE2 4HH, UK. 23 Centre for Big Data Research in Health, University of New South Wales,
Sydney, New South Wales 2052, Australia. 24 Department of Haematology, Royal Victoria Inﬁrmary, Newcastle upon Tyne NE1 4LP, UK. 25Department of
Public Health, Clinical and Molecular Medicine, University of Cagliari, Monserrato, Cagliari 09042, Italy. 26Department of Environmental Health Sciences,
Yale School of Public Health, New Haven, Connecticut 06520, USA. 27 Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria 3004,
Australia. 28 Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria
3010, Australia. 29Westat, Rockville, Maryland 20850, USA. 30Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. 31 Department of
Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA. 32Department of Epidemiology Research, Division of Health Surveillance and Research, Statens
Serum Institut, 2300 Copenhagen, Denmark. 33 Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, USA.
34Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 75105 Uppsala, Sweden. 35 Epidemiology Research
Program, American Cancer Society, Atlanta, Georgia 30303, USA. 36Department of Internal Medicine, Carver College of Medicine, The University of Iowa,
Iowa City, Iowa 52242, USA. 37 Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California 94118, USA.
38Division of Endocrinology, Diabetes and Metabolism, Ohio State University, Columbus, Ohio 43210, USA. 39 Division of Public Health Sciences, Fred
Hutchinson Cancer Research Center, Seattle, Washington 98117, USA. 40 Cancer Epidemiology Research Programme, Catalan Institute of Oncology-IDIBELL,
L’Hospitalet de Llobregat, Barcelona 08908, Spain. 41 CIBER de Epidemiologı´a y Salud Pu´blica (CIBERESP), Barcelona 08036, Spain. 42 The Tisch Cancer
Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA. 43 International Agency for Research on Cancer, Lyon 69372, France.
44 Registre des He´mopathies Malignes de Coˆte d’Or, University of Burgundy and Dijon University Hospital, Dijon 21070, France. 45 Department of
Computational Biology, St Jude Children’s Research Hospital, Memphis, Tennessee 38105, USA. 46 Department of Family Medicine and Public Health
Sciences, Wayne State University, Detroit, Michigan 48201, USA. 47 School of Public Health, Imperial College London, London W2 1PG, UK. 48MRC-PHE
Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK. 49 Human Genetics Foundation, 10126 Turin, Italy.
50 Institute for Risk Assessment Sciences, Utrecht University, Utrecht 3508 TD, The Netherlands. 51 Julius Center for Health Sciences and Primary Care,
University Medical Center Utrecht, Utrecht 3584 CX, The Netherlands. 52 Genetic Epidemiology Laboratory, Department of Pathology, University of
Melbourne, Melbourne, Victoria 3010, Australia. 53 Epidemiology of Childhood and Adolescent Cancers Group, Inserm, Center of Research in Epidemiology
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14175 ARTICLE
NATURE COMMUNICATIONS | 8:14175 |DOI: 10.1038/ncomms14175 | www.nature.com/naturecommunications 11
and Statistics Sorbonne Paris Cite´ (CRESS), Paris F-94807, France. 54 Universite´ Paris Descartes, 75270 Paris, France. 55 Cancer Control Research, BC Cancer
Agency, Vancouver, British Columbia, Canada V5Z1L3. 56 School of Population and Public Health, University of British Columbia, Vancouver, British Columbia,
Canada V6T1Z3. 57 Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115, USA. 58 Department of
Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts 02115, USA. 59Department of Biomedical Science, University of Cagliari,
Monserrato, Cagliari 09042, Italy. 60 Department of Haematology, Queen Elizabeth Hospital, Gateshead NE9 6SX, UK. 61 Interdisciplinary Department of
Medicine, University of Bari, Bari 70124, Italy. 62 Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3BX, UK.
63 Environmental and Occupational Epidemiology Unit, Cancer Prevention and Research Institute (ISPO), Florence 50139, Italy. 64 Department of
Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. 65 Carolina Center for Genome Sciences, University of
North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. 66Queens Centre for Haematology and Oncology, Castle Hill Hospital, Hull and East
Yorkshire NHS Trust, Cottingham HU16 5JQ, UK. 67Department of Haematology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK. 68Division of
Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK. 69 Cardiff and Vale National Health Service Trust, Heath Park, Cardiff
CF14 4XW, UK. 70 Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, Jeddah 21589, Kingdom of Saudi Arabia.
71 Division of Molecular Pathology, The Institute of Cancer Research, London SW7 3RP, UK. 72 Unitat de Hematologı´a, Hospital Clı´nic, IDIBAPS, Universitat de
Barcelona, Barcelona 08036, Spain. 73 Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA. * These authors contributed
equally to this work. ** These authors jointly supervised the work.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14175
12 NATURE COMMUNICATIONS | 8:14175 |DOI: 10.1038/ncomms14175 | www.nature.com/naturecommunications
